

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U <sub>AV</sub> = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(1) Sodium</b>					170																170	167	98%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		131	2,3	1,8	170									CRV	130,3	2,0	5%	123	137	170	168	99%	
(2) Indirect ISE		131	2,1	1,6	149	0															149		
(3) Direct ISE		133	3,0	2,3	19	0															19		
Other					2	0															2		
														2x 99									
<b>Sample B</b>		142	2,3	1,6	170									CRV	141	2,1	5%	133	149	170	168	99%	
(2) Indirect ISE		142	2,2	1,6	149	0															149		
(3) Direct ISE		143	2,6	1,8	19	0															19		
Other					2	0															2		
														2x 99									
<b>(2) Potassium</b>					170																170	166	98%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		4,95	0,11	2,3	170									CRV	4,887	0,079	7%	4,54	5,23	170	166	98%	
(2) Indirect ISE		4,95	0,11	2,2	150	0															150		
(3) Direct ISE		4,96	0,14	2,9	18	0															18		
Other					2	0															2		
														2x 99									
<b>Sample B</b>		6,86	0,14	2,0	170									CRV	6,729	0,10	7%	6,25	7,2	170	168	99%	
(2) Indirect ISE		6,86	0,14	2,0	150	0															150		
(3) Direct ISE		6,83	0,20	2,9	18	0															18		
Other					2	0															2		
														2x 99									
<b>(3) Chloride</b>					170						170	165	97%										0
Samples and groups	[mmol/L]																						
<b>Sample A</b>		113	3,3	2,9	170		CVP	113	0,62	7%	105	121		170	166	98%							0
(3) Indirect ISE		113	3,4	3,0	150	0								150									
(4) Direct ISE		113	2,5	2,2	16	0								16									
Other					4	0								4									
							3x 2, 1x 99																
<b>Sample B</b>		132	3,5	2,6	170		CVP	132	0,65	7%	122	142		170	167	98%							0
(3) Indirect ISE		132	3,5	2,6	150	0								150									
(4) Direct ISE		131	3,4	2,6	16	0								16									
Other					4	0								4									
							3x 2, 1x 99																
<b>(4) Calcium</b>					158																158	157	99%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		3,44	0,08	2,4	158									CRV	3,471	0,052	8%	3,19	3,75	158	157	99%	
(2) Phot. with o-cresolftalexon		3,48	0,12	3,6	20	0															20		
(3) Photom. with arsenazo III		3,41	0,06	2,0	84	0															84		

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

Test	[unit]	Comparability					Traceability																		
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>											
<b>(4) Calcium</b>					158							0				158	157	99%							
Samples and groups	[mmol/L]																								
<b>Sample A</b>		3,44	0,08	2,4	158							0	CRV	3,471	0,052	8%	3,19	3,75	158	157	99%				
(4) Complex Ca-NM-BAPTA		3,48	0,06	1,8	48	0													48						
(6) ISE		3,43	0,09	2,8	6	0														6					
<b>Sample B</b>		2,52	0,05	2,3	158							0	CRV	2,509	0,038	8%	2,3	2,71	158	157	99%				
(2) Phot. with o-cresolftalexon		2,53	0,08	3,5	20	0														20					
(3) Photom. with arsenazo III		2,51	0,05	2,1	84	0														84					
(4) Complex Ca-NM-BAPTA		2,53	0,05	2,1	48	0														48					
(6) ISE		2,53	0,02	0,88	6	0														6					
<b>(5) Inorganic phosphate</b>					151							151	149	99%									0		
Samples and groups	[mmol/L]																								
<b>Sample A</b>		1,04	0,03	3,6	151	CVP	1,04	0,0074	10%	0,936	1,15	151	149	99%									0		
(1) UV-molybdate method		1,04	0,03	3,5	147	0						147													
Other					4	0						4													
<b>Sample B</b>		1,73	0,05	2,9	151	CVP	1,73	0,0100	10%	1,55	1,91	151	150	99%									0		
(1) UV-molybdate method		1,73	0,04	2,9	147	0						147													
Other					4	0						4													
<b>(6) Iron</b>					143							143	141	99%									0		
Samples and groups	[µmol/L]																								
<b>Sample A</b>		38,5	1,1	2,8	143	CVP	38,5	0,22	15%	32,7	44,3	143	141	99%									0		
(2) Method with ferrozine/ferene		38,7	1,1	2,8	111	0						111													
(4) Method with TPTZ		38,0	0,75	2,0	32	0						32													
<b>Sample B</b>		18,8	0,74	3,9	143	CVP	18,8	0,15	15%	15,9	21,7	143	142	99%									0		
(2) Method with ferrozine/ferene		19,0	0,68	3,6	111	0						111													
(4) Method with TPTZ		18,3	0,58	3,2	32	0						32													
<b>(7) Magnesium</b>					150							0											150	141	94%
Samples and groups	[mmol/L]																								
<b>Sample A</b>		0,755	0,03	3,9	150							0	CRV	0,725	0,011	15%	0,616	0,834	150	143	95%				
(2) Photometry		0,757	0,02	3,9	130	0																130			
(4) UV enzyme method		0,737	0,02	3,1	20	0																20			
<b>Sample B</b>		1,47	0,04	3,0	150							0	CRV	1,457	0,022	15%	1,23	1,68	150	147	98%				
(2) Photometry		1,47	0,04	3,2	130	0																130			
(4) UV enzyme method		1,47	0,03	2,3	20	0																20			
<b>(8) Lithium</b>					26							0											26	22	85%
Samples and groups	[mmol/L]																								
<b>Sample A</b>		1,57	0,06	4,4	26							0	CRV	1,58	0,024	12%	1,39	1,77	26	24	92%				
(1) Flame emission phot.		1,58	0,08	5,6	6	0																6			
(3) ISE		1,55	0,09	6,2	8	0																8			
(4) Photometry		1,55	0,06	4,3	8	0																8			
Other					4	2																4			
<b>Sample B</b>		0,830	0,02	3,3	26							0	CRV	0,808	0,012	12%	0,711	0,905	26	22	85%				
(1) Flame emission phot.		0,835	0,02	2,7	6	0																6			

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(8) Lithium</b>					26							0									26	22	85%
Samples and groups	[mmol/L]																						
<b>Sample B</b>		0,830	0,02	3,3	26							0		CRV	0,808	0,012	12%	0,711	0,905	26	22	85%	
(3) ISE		0,840	0,01	1,8	8	0															8		
(4) Photometry		0,785	0,08	10	8	0															8		
Other					4	2															4		
														2x 0, 2x 2									
<b>(9) Total protein</b>					163							0									163	159	98%
Samples and groups	[g/L]																						
<b>Sample A</b>		67,5	1,9	2,8	163							0		CRV	67,99	0,80	9%	61,8	74,2	163	160	98%	
(1) Biuret		67,5	1,9	2,8	163	0															163		
<b>Sample B</b>		58,7	1,6	2,8	163							0		CRV	59,4	0,70	9%	54	64,8	163	160	98%	
(1) Biuret		58,7	1,6	2,8	163	0															163		
<b>(10) Albumin</b>					160							160	158	99%							0		
Samples and groups	[g/L]																						
<b>Sample A</b>		43,2	1,6	3,8	160	CVP	43,2	0,32	10%	38,8	47,6	160	159	99%							0		
(1) BCG		43,4	1,6	3,7	146	0						146											
(2) BCP		41,6	1,1	2,6	14	0						14											
<b>Sample B</b>		37,7	1,5	4,0	160	CVP	37,7	0,29	10%	33,9	41,5	160	159	99%							0		
(1) BCG		37,9	1,5	3,9	146	0						146											
(2) BCP		36,1	0,97	2,7	14	0						14											
<b>(11) Osmolality</b>					71							71	71	100%							0		
Samples and groups	[mmol/kg]																						
<b>Sample A</b>		309	6,3	2,1	71	CVP	309	1,8	5%	293	325	71	71	100%							0		
(1) Osmometer		309	6,3	2,1	71	0						71											
<b>Sample B</b>		328	6,8	2,1	71	CVP	328	2,0	5%	311	345	71	71	100%							0		
(1) Osmometer		328	6,8	2,1	71	0						71											
<b>(12) Lactate</b>					86							86	83	97%							0		
Samples and groups	[mmol/L]																						
<b>Sample A</b>		2,01	0,09	4,7	86	CVP	2,01	0,025	15%	1,7	2,32	86	83	97%							0		
(1) UV enzyme method		2,01	0,08	4,4	37	0						37											
(2) Enzyme electrodes		2,21	0,28	13	6	0						6											
(3) Photometric enzyme method		2,00	0,09	4,6	43	0						43											
<b>Sample B</b>		3,36	0,13	3,9	86	CVP	3,36	0,035	15%	2,85	3,87	86	84	98%							0		
(1) UV enzyme method		3,37	0,16	4,6	37	0						37											
(2) Enzyme electrodes		3,31	0,29	8,7	6	0						6											
(3) Photometric enzyme method		3,36	0,11	3,2	43	0						43											
<b>(13) Bilirubin total</b>					168							0									168	166	99%
Samples and groups	[µmol/L]																						
<b>Sample A</b>		29,7	2,6	8,7	168							0		CRV	29,6	0,90	21%	23,3	35,9	168	166	99%	
(1) Jendrassik-Gróf		30,5	2,5	8,1	30	0															30		
(2) DCA, DPD		29,4	2,6	9,0	122	0															122		
(4) Oxidation-reduction methods		30,8	0,90	2,9	15	0															15		
Other					1	0															1		
<b>Sample B</b>		56,9	4,0	7,0	168							0		CRV	57,5	1,5	21%	45,4	69,6	168	167	99%	

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

Test	[unit]	Comparability					Traceability																
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(13) Bilirubin total</b>					168							0									168	166	99%
Samples and groups	[µmol/L]																						
<b>Sample B</b>		56,9	4,0	7,0	168							0		CRV	57,5	1,5	21%	45,4	69,6	168	167	99%	
(1) Jendrassik-Gróf		58,0	3,2	5,5	30	0															30		
(2) DCA, DPD		56,3	4,1	7,2	122	0															122		
(4) Oxidation-reduction methods		59,6	2,0	3,3	15	0															15		
Other					1	0															1		
														1x0									
<b>(15) Cholesterol</b>					161							7	7	100%							154	143	93%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		3,90	0,15	3,9	161							7	7	100%							154	152	99%
(1) Enzyme CHOD-PAP		3,91	0,15	3,7	154	0								CRV	3,955	0,040	9%	3,59	4,32	154			
(1) Enzyme CHOD-PAP; (149) Siemens (Dade)		3,54	0,05	1,7	7	0	CVPG	3,54	0,058	6,5%	3,3	3,78									7		
<b>Sample B</b>		3,32	0,14	4,1	161							7	7	100%							154	145	94%
(1) Enzyme CHOD-PAP		3,33	0,13	3,8	154	0								CRV	3,459	0,035	9%	3,14	3,78	154			
(1) Enzyme CHOD-PAP; (149) Siemens (Dade)		2,92	0,13	4,6	7	0	CVPG	2,92	0,13	6,5%	2,73	3,11									7		
<b>(16) Glucose</b>					173							0									173	170	98%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		4,19	0,12	2,8	173							0		CRV	4,189	0,042	8%	3,85	4,53	173	171	99%	
(1) GOD photometry		4,27	0,12	2,7	35	0															35		
(2) GOD electrochemical		4,18	0,11	2,7	5	0															5		
(3) Method with hexokinase		4,18	0,11	2,6	133	0															133		
<b>Sample B</b>		8,93	0,21	2,3	173							0		CRV	8,819	0,088	8%	8,11	9,53	173	171	99%	
(1) GOD photometry		8,98	0,25	2,8	35	0															35		
(2) GOD electrochemical		8,72	0,12	1,4	5	0															5		
(3) Method with hexokinase		8,93	0,20	2,2	133	0															133		
<b>(17) Uric acid</b>					167							0									167	165	99%
Samples and groups	[µmol/L]																						
<b>Sample A</b>		603	20	3,4	167							0		CRV	614,3	6,1	12%	540	689	167	166	99%	
(2) Enzyme-photomet. m.		603	20	3,4	167	0															167		
<b>Sample B</b>		244	9,9	4,1	167							0		CRV	248,1	2,5	12%	218	278	167	165	99%	
(2) Enzyme-photomet. m.		244	9,9	4,1	167	0															167		
<b>(18) Urea</b>					170							0									170	169	99%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		31,1	1,2	3,7	170							0		CRV	32,33	0,32	15%	27,4	37,2	170	169	99%	
(1) UV enzymatic m.(GMD)		31,1	1,2	3,7	164	0															164		
(5) Electrochemical m.		31,8	0,96	3,0	5	0															5		
Other					1	0															1		
<b>Sample B</b>		24,8	0,88	3,5	170							0		CRV	25,46	0,25	15%	21,6	29,3	170	169	99%	
(1) UV enzymatic m.(GMD)		24,8	0,89	3,6	164	0															164		
(5) Electrochemical m.		25,1	0,52	2,1	5	0															5		
Other					1	0															1		
														1x2									

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

Test	[unit]	Comparability						Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(19) Creatinine</b>					173							0									173	171	99%
Samples and groups	[µmol/L]																						
<b>Sample A</b>		391	12	3,1	173							0		CRV	391	3,9	13%	340	442	173	172	99%	
(1) Jaffé with deprot.		391	10	2,7	5	0														5			
(2) Jaffé without depro. (with corr.)		388	15	3,8	79	0														79			
(3) Enzyme		394	10	2,6	86	0														86			
Other					3	0														3			
<b>Sample B</b>		500	17	3,4	173							0		3x4 CRV	501,5	5,0	13%	436	567	173	171	99%	
(1) Jaffé with deprot.		498	9,3	1,9	5	0														5			
(2) Jaffé without depro. (with corr.)		493	19	3,8	79	0														79			
(3) Enzyme		506	13	2,6	86	0														86			
Other					3	0														3			
														3x4									
<b>(20) Triglycerides</b>					161							0									161	156	97%
Samples and groups	[mmol/L]																						
<b>Sample A</b>		0,908	0,04	5,1	161							0		CRV	0,928	0,093	15%	0,788	1,07	161	156	97%	
(1) GPO-PAP		0,908	0,04	5,1	157	0														157			
Other					4	0														4			
<b>Sample B</b>		1,26	0,05	4,3	161							0		4x2 CRV	1,254	0,015	15%	1,06	1,45	161	159	99%	
(1) GPO-PAP		1,26	0,05	4,2	157	0														157			
Other					4	0														4			
														4x2									
<b>(21) ALP</b>					165							58	57	98%							107	106	99%
Samples and groups	[µkat/L]																						
<b>Sample A</b>		2,73	0,37	13	165							58	57	98%							107	107	100%
(3) IFCC method		2,90	0,30	10	107	0									CRV	2,894	0,070	24%	2,19	3,59	107		
(3) IFCC method; (60) Roche		2,41	0,11	4,4	58	0	CVPG	2,41	0,034	18%	1,97	2,85											
<b>Sample B</b>		7,24	1,2	16	165							58	57	98%							107	106	99%
(3) IFCC method		7,83	0,98	13	107	0									CRV	7,738	0,18	24%	5,88	9,6	107		
(3) IFCC method; (60) Roche		6,22	0,29	4,7	58	0	CVPG	6,22	0,094	18%	5,1	7,34											
<b>(22) alpha-amylase</b>					164							7	7	100%							157	154	98%
Samples and groups	[µkat/L]																						
<b>Sample A</b>		7,17	0,40	5,5	164							7	7	100%							157	155	99%
(1) IFCC method		7,14	0,36	5,1	157	0									CRV	7,243	0,20	15%	6,15	8,33	157		
(1) IFCC method; (149) Siemens (Dade)		8,99	0,26	2,9	7	0	CVPG	8,99	0,25	9,5%	8,13	9,85											
<b>Sample B</b>		5,48	0,30	5,6	164							7	7	100%							157	154	98%
(1) IFCC method		5,46	0,28	5,1	157	0									CRV	5,518	0,15	15%	4,69	6,35	157		
(1) IFCC method; (149) Siemens (Dade)		6,88	0,36	5,3	7	0	CVPG	6,88	0,35	9,5%	6,22	7,54											
<b>(23) AST</b>					170							0									170	166	98%
Samples and groups	[µkat/L]																						
<b>Sample A</b>		1,69	0,09	5,4	170							0		CRV	1,675	0,037	15%	1,42	1,93	170	167	98%	
(1) IFCC method		1,69	0,09	5,4	170	0														170			
<b>Sample B</b>		4,07	0,21	5,1	170							0		CRV	4,026	0,090	15%	3,42	4,63	170	167	98%	

## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

Test	[unit]	Comparability					Traceability															
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>								
<b>(23) AST</b>					170							0				170	166	98%				
Samples and groups	[µkat/L]																					
<b>Sample B</b>		4,07	0,21	5,1	170							0	CRV	4,026	0,090	15%	3,42	4,63	170	167	98%	
(1) IFCC method		4,07	0,21	5,1	170	0													170			
<b>(24) ALT</b>					171							0							171	168	98%	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		4,28	0,20	4,7	171							0	CRV	4,303	0,11	15%	3,65	4,95	171	168	98%	
(1) IFCC method		4,28	0,20	4,7	171	0													171			
<b>Sample B</b>		3,78	0,18	4,9	171							0	CRV	3,826	0,085	15%	3,25	4,4	171	168	98%	
(1) IFCC method		3,78	0,18	4,9	171	0													171			
<b>(26) CK</b>					151							0							151	147	97%	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		8,85	0,57	6,5	151							0	CRV	8,778	0,24	20%	7,02	10,6	151	147	97%	
(1) IFCC method		8,85	0,57	6,5	151	0													151			
<b>Sample B</b>		5,91	0,40	6,7	151							0	CRV	6,078	0,19	20%	4,86	7,3	151	149	99%	
(1) IFCC method		5,91	0,40	6,7	151	0													151			
<b>(27) gamma-GT</b>					168							0							168	163	97%	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		1,34	0,04	3,6	168							0	CRV	1,395	0,035	15%	1,18	1,61	168	164	98%	
(1) IFCC method		1,34	0,04	3,6	167	0													167			
Other					1	0														1		
<b>Sample B</b>		3,22	0,12	3,7	168							0	CRV	3,242	0,080	15%	2,75	3,73	168	165	98%	
(1) IFCC method		3,22	0,12	3,7	167	0													167			
Other					1	0														1		
													1x 99									
<b>(28) LD</b>					129							0							129	128	99%	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		4,54	0,18	4,0	129							0	CRV	4,498	0,098	18%	3,68	5,31	129	128	99%	
(3) IFCC method		4,54	0,18	4,0	129	0													129			
<b>Sample B</b>		3,34	0,17	5,0	129							0	CRV	3,302	0,073	18%	2,7	3,9	129	128	99%	
(3) IFCC method		3,34	0,17	5,0	129	0													129			
<b>(29) Lipase</b>					103							88	76	86%							0	
Samples and groups	[µkat/L]																					
<b>Sample A</b>		1,30	0,16	13	103							88	86	98%							0	
(0) Not specified; (1) Abbott		1,38	0,09	7,0	8	0	CVPG	1,38	0,073	24%	1,04	1,72										
(0) Not specified; (12) Beckman Coulter		1,20	0,28	23	8	0	CVPG	1,2	0,21	24%	0,912	1,49										
(0) Not specified; (58) Beckman Coulter (Olympus)		1,39	0,07	5,2	26	0	CVPG	1,39	0,035	24%	1,05	1,73										
(0) Not specified; (60) Roche		1,24	0,13	10	41	0	CVPG	1,24	0,048	24%	0,942	1,54										
(0) Not specified; (179) Siemens (Bayer)		1,54	0,08	5,3	5	0	CVPG	1,54	0,23	24%	1,17	1,91										
Other					15	0																
<b>Sample B</b>		4,86	1,1	23	103							88	77	88%							0	
(0) Not specified; (1) Abbott		5,41	0,46	8,5	8	0	CVPG	5,41	0,35	24%	4,11	6,71										



## Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of groups n = 5

## EQA round: AKS1/18 - Basic Clinical Chemistry - Serum

Dead line: 02.02.2018

Test	[unit]						Comparability						Traceability										
		RoM	SD	CV [%]	N <sub>tot</sub>	N <sub>out</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	AV	U <sub>AV</sub>	D <sub>max</sub>	LL	UL	N <sub>eva</sub>	N <sub>suc</sub>	S <sub>rel</sub>	
<b>(36) Calcium ionised</b>					31						31	28	90%							0			
Samples and groups	[mmol/L]																						
<b>Sample B</b>		1,74	0,06	3,7	31	CVP	1,74	0,028	10%	1,56	1,92	31	28	90%						0			
(2) Direct ISE		1,75	0,06	3,6	28							28											
Other					3							3											
						3x 1																	

st\_kn\_np

End of report

Printed: 13.02.2018